198 related articles for article (PubMed ID: 14760171)
21. [Sirolimus-eluting vs paclitaxel-eluting stents -- the trials confirm differences in clinical outcome].
Gil RJ
Kardiol Pol; 2005 Nov; 63(5):574-6; discussion 577. PubMed ID: 16362868
[No Abstract] [Full Text] [Related]
22. Sirolimus- vs paclitaxel-eluting stents in de novo coronary artery lesions: the REALITY trial: a randomized controlled trial.
Morice MC; Colombo A; Meier B; Serruys P; Tamburino C; Guagliumi G; Sousa E; Stoll HP;
JAMA; 2006 Feb; 295(8):895-904. PubMed ID: 16493102
[TBL] [Abstract][Full Text] [Related]
23. A meta-analysis of clinical trials of paclitaxel- and sirolimus-eluting stents in patients with obstructive coronary artery disease.
Shafiq N; Malhotra S; Pandhi P; Grover A; Uboweja A
Br J Clin Pharmacol; 2005 Jan; 59(1):94-101. PubMed ID: 15606446
[TBL] [Abstract][Full Text] [Related]
24. Paclitaxel-eluting stents: current clinical experience.
Grube E; Buellesfeld L
Am J Cardiovasc Drugs; 2004; 4(6):355-60. PubMed ID: 15554720
[TBL] [Abstract][Full Text] [Related]
25. Clinical trials in restenosis with 7-hexanoyltaxol and paclitaxel-eluting stents.
Doggrell SA
Expert Rev Cardiovasc Ther; 2004 Sep; 2(5):745-52. PubMed ID: 15350175
[TBL] [Abstract][Full Text] [Related]
26. Drug eluting stents: maximising benefit and minimising cost.
Gunn J; Morton AC; Wales C; Newman CM; Crossman DC; Cumberland DC
Heart; 2003 Feb; 89(2):127-31. PubMed ID: 12527654
[TBL] [Abstract][Full Text] [Related]
27. Early experiences and clinical implications of restenosis and drug-eluting stents: Part 2.
Chong PH; Cheng JW
Ann Pharmacother; 2004 May; 38(5):845-52. PubMed ID: 15039482
[TBL] [Abstract][Full Text] [Related]
28. [Do drug-eluting stents influence the spectrum of coronary artery bypass surgery?].
Matschke K; Tugtekin SM; Kappert U; Jung F; Park JW; Knaut M
Herz; 2004 Mar; 29(2):201-7. PubMed ID: 15057442
[TBL] [Abstract][Full Text] [Related]
29. A hierarchical Bayesian meta-analysis of randomised clinical trials of drug-eluting stents.
Babapulle MN; Joseph L; Bélisle P; Brophy JM; Eisenberg MJ
Lancet; 2004 Aug 14-20; 364(9434):583-91. PubMed ID: 15313358
[TBL] [Abstract][Full Text] [Related]
30. Paclitaxel-eluting or sirolimus-eluting stents to prevent restenosis in diabetic patients.
Dibra A; Kastrati A; Mehilli J; Pache J; Schühlen H; von Beckerath N; Ulm K; Wessely R; Dirschinger J; Schömig A;
N Engl J Med; 2005 Aug; 353(7):663-70. PubMed ID: 16105990
[TBL] [Abstract][Full Text] [Related]
31. Polymer-based paclitaxel-eluting stent for treatment of chronic total occlusions of native coronaries: results of a Taxus CTO registry.
Buellesfeld L; Gerckens U; Mueller R; Schmidt T; Grube E
Catheter Cardiovasc Interv; 2005 Oct; 66(2):173-7. PubMed ID: 16144017
[TBL] [Abstract][Full Text] [Related]
32. Drug-eluting stents for in-stent restenosis and acute myocardial infarction: present data from nonrandomized studies.
Schofer J; Bode C; Silber S
Herz; 2004 Mar; 29(2):195-200. PubMed ID: 15057441
[TBL] [Abstract][Full Text] [Related]
33. Cost effectiveness of the sirolimus-eluting stent in high-risk patients in Canada: an analysis from the C-SIRIUS trial.
Rinfret S; Cohen DJ; Tahami Monfared AA; Lelorier J; Mireault J; Schampaert E
Am J Cardiovasc Drugs; 2006; 6(3):159-68. PubMed ID: 16780389
[TBL] [Abstract][Full Text] [Related]
34. Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
Colombo A; Moses JW; Morice MC; Ludwig J; Holmes DR; Spanos V; Louvard Y; Desmedt B; Di Mario C; Leon MB
Circulation; 2004 Mar; 109(10):1244-9. PubMed ID: 14981005
[TBL] [Abstract][Full Text] [Related]
35. Release profiles in drug-eluting stents: issues and uncertainties.
Venkatraman S; Boey F
J Control Release; 2007 Jul; 120(3):149-60. PubMed ID: 17582635
[TBL] [Abstract][Full Text] [Related]
36. A multicenter, randomized study to test immunosuppressive therapy with oral prednisone for the prevention of restenosis after percutaneous coronary interventions: cortisone plus BMS or DES versus BMS alone to eliminate restenosis (CEREA-DES) - study design and rationale.
Ribichini F; Tomai F; De Luca G; Boccuzzi G; Presbitero P; Pesarini G; Ferrero V; Ghini AS; Pastori F; De Luca L; Zavalloni D; Soregaroli D; Garbo R; Franchi E; Marino P; Minelli M; Vassanelli C
J Cardiovasc Med (Hagerstown); 2009 Feb; 10(2):192-9. PubMed ID: 19377384
[TBL] [Abstract][Full Text] [Related]
37. [When are drug-eluting stents effective? A critical analysis of the presently available data].
Silber S
Z Kardiol; 2004 Sep; 93(9):649-63. PubMed ID: 15365732
[TBL] [Abstract][Full Text] [Related]
38. A stent is not just a stent: Stent construction and design do matter in its clinical performance.
Lau KW; Johan A; Sigwart U; Hung JS
Singapore Med J; 2004 Jul; 45(7):305-11; quiz 312. PubMed ID: 15221045
[TBL] [Abstract][Full Text] [Related]
39. Outcomes of paclitaxel-eluting stent implantation in patients with stenosis of the left anterior descending coronary artery.
Dangas G; Ellis SG; Shlofmitz R; Katz S; Fish D; Martin S; Mehran R; Russell ME; Stone GW;
J Am Coll Cardiol; 2005 Apr; 45(8):1186-92. PubMed ID: 15837247
[TBL] [Abstract][Full Text] [Related]
40. Post-sirolimus-eluting stent restenosis treated with repeat percutaneous intervention: late angiographic and clinical outcomes.
Lemos PA; van Mieghem CA; Arampatzis CA; Hoye A; Ong AT; McFadden E; Sianos G; van der Giessen WJ; de Feyter PJ; van Domburg RT; Serruys PW
Circulation; 2004 Jun; 109(21):2500-2. PubMed ID: 15148279
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
